A Phase II/III Study of F520 Combined With Paclitaxel Plus Carboplatin in the Treatment of Cancer of Unknown Primary (CUP)
A phase 2/3 trial of F520 combined with chemotherapy in cancer of unknown primary, run by Shandong New Time Pharmaceutical Co., LTD, now recruiting.
Overview
A Phase II/III Study of F520 Combined With Paclitaxel Plus Carboplatin in the Treatment of Cancer of Unknown Primary (CUP) is a phase 2/3 interventional study registered as NCT07761429 by Shandong New Time Pharmaceutical Co., LTD, with 402 participants planned, started 2026-07-08 and due to reach its primary completion in 2027-12-30. Interventions recorded: F520 combined with chemotherapy and placebo combined with chemotherapy.
Setting
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II/III Study Evaluating the Safety and Efficacy of F520 Combined With Paclitaxel Plus Carboplatin as First-line Treatment for Cancer of Unknown Primary
Phase
Phase 2/3
Sponsor
Shandong New Time Pharmaceutical Co., LTD
Registry
Enrolled
402